Navigation Links
Xceed Molecular Features Ziplex(R) Automated Gene-Expression System at the Biomarker World Congress, Booth 16
Date:5/16/2008

Xceed's Dr. David Englert and Dr. Zhe Zhang of Children's Hospital of Philadelphia will present data at a luncheon workshop on Wednesday, May

21st

WELLESLEY, Mass., May 16 /PRNewswire/ -- Xceed Molecular, a pioneer in the development of cost-effective, easy-to-use gene-expression analysis systems, announced that the company will feature its Ziplex Automated Gene-Expression System at Biomarker World Congress, booth 16. Currently available for research use only in the US and Canada, the Ziplex System is the first integrated system for automated gene-expression analysis. It comprises an automated hybridization workstation, TipChip consumable arrays, reagents, and analysis/reporting software. Biomarker World Congress takes place May 19-21, 2008, at the Loews Philadelphia Hotel in Pennsylvania.

"Translational research (the movement of existing gene-expression biomarkers from basic science into routine clinical use for patient diagnostics) -- and the ultimate goal of personalized medicine -- has been hampered because the available technology to process microarrays is complex, expensive, and time-consuming," said Xceed's President and CEO, David Deems. "Results from traditional technology are also prone to unacceptable levels of variability to meet the rigorous performance and quality-control needs of the clinical-diagnostic laboratory. Xceed designed the Ziplex System with turnkey functionality and significant advances in automation, array format, fluidics, parallel sample processing, and analytics to minimize complexity, user interaction, and variability between users and sites. Our goal: to make routine molecular diagnostics easy, reproducible, and affordable to serve the needs of both clinical research and clinical-diagnostic settings -- which demand that results remain consistent even when samples are run by different people, at different times, or in different sites."

Luncheon Workshop

Xceed is hosting a luncheon workshop from 12 to 1:30 pm, on Wednesday, May 21, 2008, in the Howe Room of the Loews Philadelphia Hotel.

Ziplex System for Focused Content, Multiplexed Gene-Expression Analysis -- Introduction and Study Results

David Englert, Ph.D., VP, Technology Development, Xceed Molecular, Toronto.

Identification of a Diagnostic Classifier of Cornelia de Lange Syndrome, an Often Misdiagnosed and Little-Known Genetic Syndrome, Through a Stepwise and Multi-Platform Procedure

Zhe Zhang, Ph.D., Bioinformatics Core, Center for Biomedical Informatics, Children's Hospital of Philadelphia

Dr. Zhe Zhang is also presenting a poster on the subject, which will be available for viewing throughout the conference (Poster #11).

About Xceed Molecular

Xceed's vision is to advance molecular diagnostics by successfully translating novel multiplex tests into routine clinical practice and to create robust diagnostic solutions to improve disease outcomes. Our products comprise the Ziplex(R) System for automated gene-expression analysis (available in the US and Canada for research use only), gene expression services, and pre-configured arrays. Xceed is also developing multiplexed genomic tests for the Ziplex platform, both internally and with strategic partners. Xceed's R&D and manufacturing are headquartered in Toronto, Ontario, with executive offices in Wellesley, Massachusetts. For more information, visit http://www.XceedMolecular.com.


'/>"/>
SOURCE Xceed Molecular
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million
2. Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007
3. Cephalons 2007 Results Exceed Full Year Sales and Earnings Guidance
4. AMDL Signs 100 Strategic Cooperation Agreements in China for Its JPGreen Clinics; Gross Sales Per Each Location Could Exceed $400,000
5. Center for Molecular Medicine Offers Xceed Ziplex(TM) Services to Research Community
6. CNCA Exceeds Standards in Nutritional Supplement Quality, Protects Public
7. CrossFire Beilstein Database Exceeds Ten Million Compounds
8. Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million
9. Pathway Diagnostics Announces Commercial Availability of Second Generation SensiTrop(TM) II Molecular HIV Co-receptor Tropism Assay
10. SimBioSys Utilizes Revolutionary Hardware Technology to Open New Frontiers in Molecular Modeling
11. DermTech Study on Melanoma Molecular Diagnostic to Be Presented at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... Feb. 17, 2017  If only one in ... a mutation-conferring resistance to chemotherapy, thousands of cancer ... has focused on finding these mutations in ever-smaller ... circulating tumor DNA in blood — to guide ... Unfortunately, however, detecting these genetic anomalies ...
(Date:2/16/2017)...  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company harnessing ... treatment for triple negative breast cancer (TNBC), announced today their ... program. The YEi Start in ... entrepreneurs grow their business in France ... selected to complete an intensive one week immersion in ...
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
Breaking Biology Technology:
(Date:2/3/2017)... A new independent identity strategy consultancy firm announces its ... to fill a critical niche in technical and policy ... Mark Crego and Janice Kephart together ... that span federal governments, the 9/11 Commission, private industry, ... has a common theme born from a shared passion ...
(Date:1/31/2017)... Jan. 31, 2017  Spero Therapeutics, LLC, a ... the treatment of bacterial infections, today announced it ... candidates from Pro Bono Bio Ltd (PBB) to ... multi-drug resistant forms of Gram-negative bacteria.   The assets ... Ltd, a PBB group company. "The ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm ... of the laboratory use of nuclear magnetic resonance ... experienced end-users and profiled current practices, developments, trends ... as well as growth and opportunities. These areas ... suppliers, NMR instruments, needs and innovation requirements, hyphenated ...
Breaking Biology News(10 mins):